NCT00263276
Completed
Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2 Trial to Evaluate the Safety and Efficacy of BMS-512148 as Monotherapy in Subjects With Type 2 Diabetes Mellitus Who Are Treatment Naive And Have Inadequate Glycemic Control on Diet and Exercise
ConditionsType 2 Diabetes
Overview
- Phase
- Phase 2
- Intervention
- dapagliflozin
- Conditions
- Type 2 Diabetes
- Sponsor
- AstraZeneca
- Enrollment
- 389
- Locations
- 5
- Primary Endpoint
- Mean change from baseline in HbA1c compared to placebo.
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
The purpose of this clinical research study is to learn if BMS-512148 is effective in controlling blood sugar levels as determined by HbA1c and fasting plasma glucose in patients who have been diagnosed with Type 2 diabetes. Patients should first try to control their diabetes with diet and exercise and should not have previously been treated for their diabetes (very short periods of time are acceptable). The safety of BMS512148 will also be studied
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients with Type 2 diabetes mellitus with inadequate glycemic control on diet and exercise. HbA1c \>= 7% and \<=10%.
- •Patient either has not been previously treated with antihyperglycemic medication or has been treated for \<30 days since diagnosis and has received less than 3 consecutive doses or 7 non-consecutive doses in the last 30 days.
- •C-peptide \> 1.0 ng/ml
- •Body Mass Index \<= 40 kg/m2
- •Serum creatinine \< 1.5 mg/dL for men or \< 1.4 mg/dL for women.
- •No overt proteinuria (microalbumin/creatinine ratio must be \<300 mg/g
Exclusion Criteria
- •Unstable renal disease
- •Patients with significant liver disease including chronic active hepatitis
- •Within the last 6 months has had any of the following cardiovascular event: myocardial infarction, unstable angina, unstable CHF,NYHA Class III or IV CHF, TIA, unstable arrhythmia or cardiac revascularization surgery.
- •Subjects with clinically significant anemia
Arms & Interventions
Arm 1
Intervention: dapagliflozin
Arm 2
Intervention: dapagliflozin
Arm 3
Intervention: dapagliflozin
Arm 4
Intervention: dapagliflozin
Arm 5
Intervention: dapagliflozin
Arm 6
Intervention: placebo
Arm 7
Intervention: metformin
Outcomes
Primary Outcomes
Mean change from baseline in HbA1c compared to placebo.
Time Frame: at 12 weeks
Secondary Outcomes
- Mean change from baseline in fasting plasma glucose, evaluate proportion of subjects who achieve a therapeutic response (HbA1c <7%); change from baseline in urinary glucose excretion(at Weeks 6 and 12)
Study Sites (5)
Loading locations...
Similar Trials
Terminated
Phase 2
Study of BMS-587101 in Patients With Moderate to Severe PsoriasisPsoriasis, Moderate to SevereNCT00162253Bristol-Myers Squibb120
Completed
Phase 3
Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 DiabetesType 2 Diabetes MellitusNCT00736879AstraZeneca497
Completed
Phase 3
A Phase III Study of BMS-512148 (Dapagliflozin) in Asian Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin AloneType 2 DiabetesNCT01095666AstraZeneca1,484
Completed
Phase 3
Add-on to Thiazolidinedione (TZD) FailuresType 2 DiabetesNCT00683878AstraZeneca972
Completed
Phase 2
A Study of BMS-582949 in Patients With Moderate to Severe Plaque PsoriasisPsoriasisNCT00399906Bristol-Myers Squibb99